HEAT BIOLOGICS DL-,0002 Forum: Community User: Newcomer35

S c h m u t z b l ä 5 t e r

Na ja irgendwie müssen sich solche *** Blätter finanzieren

Arbeitet sharedealz eigentlich mit hf zusammen. Das scheint mir so

Welchen Chart schaut ihr euch an?

WOW✌👍👍👍

Mal ein ganz schöner Ausschlag nach oben 😁

Du kannst dir doch die Präsentation selbst angucken. Oder erwartest du jetzt, dass das andere für dich machen und dir die Zusammenfassung liefern? Mal abgesehen davon, dass ich mein Geld nicht aufgrund irgendwelcher Zusammenfassungen aus Internetforen investieren würde.

Ok und was Gutes genau? :-)

Nur Gutes.

Hallo und guten Tag .Kurz zusammengefasst was bedeutet es für uns hier investierten?

https://last10k.com/sec-filings/htbx/0001553350-19-000480.htm

☝🏽 hier noch der Link zur oben genannten Präsentation 😉

https://www.sec.gov/Archives/edgar/data/1476963/000155335019000480/htbx_ex99z1.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2019 Heat Biologics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation)   001-35994 26-2844103 (Commission File Number) (IRS Employer Identification No.) 801 Capitola Drive Durham, NC  27713 (Address of principal executive offices and zip code) (919) 240-7133 (Registrant’s telephone number including area code)   N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ¨   If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨ Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0002 par value per share HTBX The Nasdaq Capital Market           Item 8.01  Other Events. Heat Biologics, Inc. (the “Company”) will be making corporate presentations over the next several weeks. In connection with the presentations, the Company intends to discuss the slide presentation attached as Exhibit 99.1 hereto, which is incorporated herein by reference.   The slide presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking” rather than historical.   The Company undertakes no duty or obligation to update or revise information included in this Current Report on Form 8-K or Exhibit 99.1 hereto. Item 9.01.  Financial Statements and Exhibits. (d) Exhibits. Exhibit Number   Description       99.1    Heat Biologics, Inc. Corporate Presentation               SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated:  May 7, 2019 HEAT BIOLOGICS, INC.             By: /s/ Jeffrey Wolf   Name: Jeffrey Wolf   Title: Chairman, President and Chief Executive Officer

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai. Das liest sich auch heute noch gut...

💰💰💰💵💵💵💰💰💰💥🚀🚀🚀